Data From Alder BioPharmaceuticals’ Proof-of-Concept Clinical Trial of ALD403 Published in Lancet Neurology …

BOTHELL, Wash., Oct. 6, 2014 (GLOBE NEWSWIRE) — Alder BioPharmaceuticals Inc. (ALDR), a clinical-stage biopharmaceutical company developing antibody therapeutics, today announced data from the proof-of-concept clinical trial of ALD403 published in the October 6, 2014 issue of Lancet Neurology demonstrates that ALD403 met the primary study endpoint and is effective for the preventative treatment of […]

The post Data From Alder BioPharmaceuticals’ Proof-of-Concept Clinical Trial of ALD403 Published in Lancet Neurology … appeared first on Posts Headache.

Teva to Acquire Labrys Biologics, Inc.: Novel Migraine Prophylaxis Treatment Adds Significant New Dimension to Teva’s …

JERUSALEM & SAN MATEO, Calif.–(BUSINESS WIRE)– Teva Pharmaceutical Industries Ltd., (TEVA) and Labrys Biologics, Inc., a privately-held development stage biotechnology company focused on treatments for chronic migraine and episodic migraine, today announced that Teva has entered into a definitive agreement to acquire Labrys, broadening Teva’s array of biotechnology assets and capabilities. Teva will acquire Labrys for $200 million in upfront payment in cash at closing as well as up to $625 million in contingent payments upon achievement of certain pre-launch …

Patient Study Highlighting Intranasal Capsaicin As An Effective Treatment Option For Rapid Pain Relief Of Severe …

NEW YORK, April 30, 2014 /PRNewswire/ — Real-world patient case series analysis supporting the use of intranasal capsaicin as an effective rapid treatment for severe headache and migraine pain will be presented at the 66th American Academy of Neurology (AAN) Annual Meeting in Philadelphia, PA on Thursday, May 1, 2014 during Poster Session VII. Intranasal capsaicin has been shown in multiple research studies to have efficacy in the treatment of migraines and cluster headaches and is thought to work by the …

Two new migraine prevention drugs show promise in small studies

There are few treatments available for the millions of people who suffer from migraines. New early-stage research offers new hope. Studies presented Tuesday at the American Academy of Neurology’s annual meeting suggest that two new drugs may prevent migraines from happening. “We’ve identified a new preventive treatment for migraines, something that reduces frequency, the number of attacks and severity of attacks, how bad the attacks are,” said Dr. Peter Goadsby, co-author of both studies and professor of neurology at Kings College, …

New Migraine Treatments Show Promise

There are few treatments available for the millions of people who suffer from migraines. New early-stage research offers new hope. Studies presented Tuesday at the American Academy of Neurology’s annual meeting suggest that two new drugs may prevent migraines from happening. “We’ve identified a new preventive treatment for migraines, something that reduces frequency, the number of attacks and severity of attacks, how bad the attacks are,” said Dr. Peter Goadsby, co-author of both studies and professor of neurology at Kings …

Data From Proof

BOTHELL, Wash., April 23, 2014 (GLOBE NEWSWIRE) — Alder Biopharmaceuticals Inc. today announced that Dr. Peter J. Goadsby, M.D., Ph.D., director, NIHR-Wellcome Trust Clinical Research Facility, King’s College London and director, Headache Center, Department of Neurology, University of California, San Francisco, will present results from a randomized, double-blind, placebo-controlled proof-of-concept clinical trial of ALD403 for the prevention of frequent episodic migraine at the American Academy of Neurology Meeting, Friday, May 2, in Philadelphia, Pennsylvania. Key points: ALD403 met the primary …

  • DON’T  LEAVE  EMPTY-HANDED !!!

    Download your FREE Report on Headache

    slide12t

    Just a sneak peek…

    • Guide to cluster headache
    • Why do you get a headache?
    • Headache and migraine pain relief through hypnotherapy
    • Can stress cause severe headache?
    • Caffeine: the culprit behind our migraines
    • Menopause and headaches
    • Sinusitis: how serious is it?
    Download It Completely FREE

    Just Insert Your Name and email

    We will also send you a Complimentary copy of our Headache Newsletter. Our newsletter subscription has the latest information on Headache and Migraine treatments.

    We respect your privacy. We will NEVER sell, rent or share your email address. That’s more than a policy, it’s our personal guarantee!

  • Now you can have the Latest News on Headache

    hedac02-220

    Worried about Headache and Migraine? You can have now information about the latest treatments and medical research. All this and more in our Headache Newsletter.slide11t

    Try it for four weeks. We will even send you FREE our bonus health e-book with your trial subscription.

    All for just ONE PENNY

    Get the latest information – don’t be left in the dark on your condition.

     CLICK HERE 

    Check our special offer: Subscribe to one newsletter, get another newsletter for FREE!